New Treatment Options for Relapsed/Recurrent DLBCL: Impact on Sequencing Therapeutic Choices - Episode 11

Third-line Treatment Options for DLBCL After CAR T-cell Therapy or ASCT in Second-line

, , ,

EP. 1: Navigating Second-Line Treatments and CAR T-Cell Therapy for DLBCL: Insights from Dr. Budde and Dr. Lunning
EP. 2: Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices
EP. 3: Dr Locke Shares Key Takeaways from ZUMA-7 and TRANSFORM Studies
EP. 4: Dr Gordon Shares Key Takeaways from ALYCANTE and PILOT for 2L CAR T-cell Transplant-Ineligible Population
EP. 5: Dr Hunter Shares Key Takeaways from L-MIND 5-Year Data and RE-MIND2 Study
EP. 6: Panel Discuses Use of CD19 Bispecifics in Sequencing
EP. 7: Panel Discusses Challenges with CAR T Therapy in R/R DLBCL, Particularly Around T-cell Exhaustion
EP. 8: Current Approach to Bridging Therapy in R/R DLBCL
EP. 9: Risk of Secondary Malignancies in Heavily Pre-Treated Population
EP. 10: Management of CRS and ICANS with CAR T-cell Therapy
Now Viewing
EP. 11: Third-line Treatment Options for DLBCL After CAR T-cell Therapy or ASCT in Second-line
EP. 12: Contemporary Sequencing CD20xCD3 Bispecific Antibody R/R DLBCL Who Have progressed beyond CAR T-cell therapy
EP. 13: Bispecific therapy – treatment setting and management of short-term adverse events
EP. 14: Bispecific therapy – management of long-term adverse events in the community setting
EP. 15: Practice Patterns and Real Use of Epcoritamab and Glofitamab
EP. 16: Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCL

Video content above is prompted by the following:

  • Please give an overview of treatment options for a patient who received 2L treatment with either CAR T-cell therapy or ASCT and has relapsed. 
    • What would be your treatment choice in the third line?
    • What key issues do you consider in your sequencing decisions?
    • Please discuss rationales for each:
  • Monoclonal antibody—tafasitamab?
  • ADC —loncastuximab, polatuzumab?
  • Would you go to CAR T after ASCT?
  • Bispecific antibody—epcoritamab or glofitamab?